


EGFR/HER2-IN-7

Cat. No.:	HY-151158
Molecular Formula:	C ₁₉ H ₂₁ N ₃ O ₂ S
Molecular Weight:	355.45
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGFR/HER2-IN-7 is a potent anticancer agent with high selectivity against MCF-7 breast cancer cells. EGFR/HER2-IN-7 is a EGFR/HER2 kinase and DHFR inhibitor, with IC ₅₀ s of 0.18 μM (EGFR), 0.146 μM (HER2), respectively. EGFR/HER2-IN-7 shows moderate inhibition on DHFR (IC ₅₀ =0.907 μM) ^[1] .																
IC₅₀ & Target	0.18 μM (EGFR); 0.146 μM (HER2); 0.907 μM (DHFR) ^[1]																
In Vitro	<p>EGFR/HER2-IN-7 (compound 27) shows remarkable broad spectrum cytotoxic potency, with an IC₅₀ value of 10.81 μM against MCF-7 breast cancer cells^[1].</p> <p>EGFR/HER2-IN-7 (72 h) displays anti-breast cancer activity with an IC₅₀ value of 8.29 μM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma</td> </tr> <tr> <td>Concentration:</td> <td>0-1 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cancer cells growth with IC₅₀s of 10.81 μM (HepG2), 8.29 μM (MCF-7), 13.78 μM (HCT-116), 16.63 μM (PC3), 7.63 μM (Hela), respectively.</td> </tr> </table> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Normal healthy cell line WI-38 (fetal lung fibroblast cells)</td> </tr> <tr> <td>Concentration:</td> <td>0-1 mM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Showed low cytotoxicity against healthy cells with high IC₅₀s of >100 μM, 67.2 μM, 54.18, 89.61 μM, 36.84 μM, 49.75 μM, respectively.</td> </tr> </table>	Cell Line:	HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma	Concentration:	0-1 mM	Incubation Time:	72 hours	Result:	Inhibited cancer cells growth with IC ₅₀ s of 10.81 μM (HepG2), 8.29 μM (MCF-7), 13.78 μM (HCT-116), 16.63 μM (PC3), 7.63 μM (Hela), respectively.	Cell Line:	Normal healthy cell line WI-38 (fetal lung fibroblast cells)	Concentration:	0-1 mM	Incubation Time:	72 hours	Result:	Showed low cytotoxicity against healthy cells with high IC ₅₀ s of >100 μM, 67.2 μM, 54.18, 89.61 μM, 36.84 μM, 49.75 μM, respectively.
Cell Line:	HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate and Hea cervical epithelioid carcinoma																
Concentration:	0-1 mM																
Incubation Time:	72 hours																
Result:	Inhibited cancer cells growth with IC ₅₀ s of 10.81 μM (HepG2), 8.29 μM (MCF-7), 13.78 μM (HCT-116), 16.63 μM (PC3), 7.63 μM (Hela), respectively.																
Cell Line:	Normal healthy cell line WI-38 (fetal lung fibroblast cells)																
Concentration:	0-1 mM																
Incubation Time:	72 hours																
Result:	Showed low cytotoxicity against healthy cells with high IC ₅₀ s of >100 μM, 67.2 μM, 54.18, 89.61 μM, 36.84 μM, 49.75 μM, respectively.																

REFERENCES

[1]. Sabry MA, et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity. Eur J Med Chem. 2022 Aug 10;241:114661.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA